Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1997-09-11
1999-11-23
Mertz, Prema
Drug, bio-affecting and body treating compositions
Lymphokine
530351, 435 695, 435325, 435358, 435360, 4352523, 4353201, A61K 3819, C07K 1452
Patent
active
059895381
ABSTRACT:
Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.
REFERENCES:
patent: 5217881 (1993-06-01), Park
patent: 5218092 (1993-06-01), Sasaki et al.
Delorme et al., Biochemistry, 31:9871-9876 (1992).
Eaton et al., "Biological Activity of Human Thrombopoietin (TPO), the C-mpl Ligand and TPO Variants and the Chromosomal Localization of TPO", Blood, 84(10), (1994); Abstract No. 948, XP 000567760.
Hoffman, et al., "Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from Ser1 to Arg246", Biochemistry, 35(47), pp. 14849-14861, (1996).
Amgen Inc.
Cook Robert R.
Levy Ron
Mertz Prema
Odre Steven
LandOfFree
Mpl ligand analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mpl ligand analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mpl ligand analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1218121